The Cure Fraction of Glioblastoma Multiforme

Smoll, Nicolas R.; Schaller, Karl; Gautschi, Oliver

doi:10.1159/000339319

Cited by 21 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More specifically, competing risks of death are likely to have caused an over-estimation of the cumulative incidence of death and an underestimation of overall survival related to this tumor [ 13 ]. Answering this question with appropriate precision requires a larger sample size analyzed using the methods of relative survival as used elsewhere [ 14 – 18 ].…”

Section: Discussionmentioning

confidence: 99%

Incidence and Overall Survival of Malignant Ameloblastoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundMalignant ameloblastoma, comprising metastasizing ameloblastoma and ameloblastic carcinoma, represents 1.6–2.2% of all odontogenic tumors. Due to its rare nature, malignant ameloblastoma has only been reported in the literature in small case series or case reports. Using the Surveillance, Epidemiology and End-Results (SEER) database, we have performed a population-based study to determine the incidence rate and the absolute survival of malignant ameloblastoma.MethodUsing the International Classification of Diseases for Oncology (ICD-O) codes 9310/3 and 9270/3, data from the SEER database were used to calculate the incidence rate and absolute survival rate of population with malignant ameloblastoma.ResultsThe overall incidence rate of malignant ameloblastoma was 1.79 per 10 million person/year. The incidence rate was higher in males than females and also higher in black versus white population. The median overall survival was 17.6 years from the time of diagnosis and increasing age was associated with a statistically significant poorer survival.ConclusionsTo our best knowledge, we report the largest population-based series of malignant ameloblastoma. The incidence rate was 1.79 per 10 million person/year and the overall survival was 17.6 years.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence and Overall Survival of Malignant Ameloblastoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Application of a cure model relies on the concept that statistical plausibility of cure can be fulfilled. In essence, if a percentage of patients can reasonably be expected not to die as a consequence of their disease, the survival curve will trend toward a plateau with the passage of time . Among patients who underwent resection for ICC, a subset did experience a plateauing of their survival after a period of time (Fig.…”

Section: Methodsmentioning

confidence: 99%

Can hepatic resection provide a long‐term cure for patients with intrahepatic cholangiocarcinoma?

Spolverato

Vitale

Cucchetti

et al. 2015

Cancer

145

View full text Add to dashboard Cite

BACKGROUND: A patient can be considered statistically cured from a specific disease when their mortality rate returns to the same level as that of the general population. In the current study, the authors sought to assess the probability of being statistically cured from intrahepatic cholangiocarcinoma (ICC) by hepatic resection. METHODS: A total of 584 patients who underwent surgery with curative intent for ICC between 1990 and 2013 at 1 of 12 participating institutions were identified. A nonmixture cure model was adopted to compare mortality after hepatic resection with the mortality expected for the general population matched by sex and age. RESULTS: The median, 1-year, 3-year, and 5-year disease-free survival was 10 months, 44%, 18%, and 11%, respectively; the corresponding overall survival was 27 months, 75%, 37%, and 22%, respectively. The probability of being cured of ICC was 9.7% (95% confidence interval, 6.1%-13.4%). The mortality of patients undergoing surgery for ICC was higher than that of the general population until year 10, at which time patients alive without tumor recurrence can be considered cured with 99% certainty. Multivariate analysis demonstrated that cure probabilities ranged from 25.8% (time to cure, 9.8 years) in patients with a single, well-differentiated ICC measuring 5 cm that was without vascular/periductal invasion and lymph nodes metastases versus <0.1% (time to cure, 12.6 years) among patients with all 6 of these risk factors. A model with which to calculate cure fraction and time to cure was developed. CONCLUSIONS: The cure model indicated that statistical cure was possible in patients undergoing hepatic resection for ICC. The overall probability of cure was approximately 10% and varied based on several tumor-specific factors. Cancer 2015;121:3998-4006.

show abstract

“…Patients who survived more than 2.5 years were considered long-term survivors; this is the period past which the risk of death is half that experienced during the period of the highest risk of death (12–15 mo). 11 …”

Section: Methodsmentioning

confidence: 99%

Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundPrevious studies have shown the individual benefits of 5-aminolevulinic acid (5-ALA) and intraoperative (i)MRI in enhancing survival for patients with high-grade glioma. In this retrospective study, we compare rates of progression-free and overall survival between patients who underwent surgical resection with the combination of 5-ALA and iMRI and a control group without iMRI.MethodsIn 200 consecutive patients with high-grade gliomas, we recorded age, sex, World Health Organization tumor grade, and pre- and postoperative Karnofsky performance status (good ≥80 and poor <80). A 0.15-Tesla magnet was used for iMRI; all patients operated on with iMRI received 5-ALA. Overall and progression-free survival rates were compared using multivariable regression analysis.ResultsMedian overall survival was 13.8 months in the non-iMRI group and 17.9 months in the iMRI group (P = .043). However, on identifying confounding variables (ie, KPS and resection status) in this univariate analysis, we then adjusted for these confounders in multivariate analysis and eliminated this distinction in overall survival (hazard ratio: 1.23, P = .34, 95% CI: 0.81, 1.86). Although 5-ALA enhanced the achievement of gross total resection (odds ratio: 3.19, P = .01, 95% CI: 1.28, 7.93), it offered no effect on overall or progression-free survival when adjusted for resection status.ConclusionsGross total resection is the key surgical variable that influences progression and survival in patients with high-grade glioma and more likely when surgical adjuncts, such as iMRI in combination with 5-ALA, are used to enhance resection.

show abstract

The Cure Fraction of Glioblastoma Multiforme

Cited by 21 publications

References 56 publications

Incidence and Overall Survival of Malignant Ameloblastoma

Incidence and Overall Survival of Malignant Ameloblastoma

Can hepatic resection provide a long‐term cure for patients with intrahepatic cholangiocarcinoma?

Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery

Contact Info

Product

Resources

About